Replies to post #246987 on Biotech Values

[ciotera]

Re: Atrasentan

I remember AbbVie got rid of it. Also bardoxolone. My bet would also be that it's not approvable.

[Whalatane]

Thx Dew. ...appreciate the DD

AbbVie3 and Chinook seem to have systemically manipulated research findings and presentation on atrasentan to obscure these trial results.

Thats quite some claim ..
Kiwi

[DewDiligence]

Muddy Waters is short KDNY—thinks Atrasentan not_approvable...

Oops!

[vinmantoo]

Muddy Waters is short KDNY—thinks Atrasentan not approvable:

I thought Muddy Waters was dead. Now wonder his stocks picks don't turn out well. ;)

[Biowatch]

NVS atrasentan meets Phase 3, 2024 FDA Filing_Planned

“Novartis Drug From $3.2B Deal Succeeds in Phase 3, 2024 FDA Filing Is Planned”

https://medcitynews.com/2023/10/novartis-drug-from-3-2b-deal-succeeds-in-phase-3-2024-fda-filing-is-planned/

Novartis drug candidate atrasentan met the main goal of a pivotal study in the chronic kidney disease IgA nepropathy. It’s one of two drugs added via the multi-billion dollar acquisition of Chinook Therapeutics; together with a homegrown therapeutic candidate, they give Novartis three different approaches to treat the rare disorder.